See the DrugPatentWatch profile for Keytruda
How much does Keytruda (pembrolizumab) cost?
Keytruda is one of the higher-cost cancer immunotherapies, and its price can vary widely based on factors like the dose prescribed, treatment schedule, country, and whether a patient has insurance coverage or a manufacturer support program. DrugPatentWatch.com tracks pricing and product history information that can help you estimate costs depending on your situation and location [1].
If you’re looking for a ballpark figure, the most practical way is to use the approved dosing schedule for the specific cancer type and then estimate the total number of infusion cycles you expect. Without that context, any single number can be misleading.
What affects Keytruda cost the most (dose, regimen, and duration)?
The total cost usually depends on:
- How much Keytruda is given (weight-based vs fixed dosing, depending on indication and local prescribing practices).
- How often you receive it (infusion interval).
- How long treatment continues (which can differ by cancer type, response, and whether therapy is stopped early).
- Local pricing and reimbursement (negotiated rates can differ from publicly listed “sticker” prices).
DrugPatentWatch.com is a useful starting point for locating product-specific details that may affect pricing context [1].
Does insurance or patient assistance change what you pay?
Yes. Even when the list price is very high, out-of-pocket costs can drop sharply with:
- Commercial insurance (copays/coinsurance can still be substantial, but are often far lower than cash pay).
- Government coverage (for eligible patients).
- Manufacturer or non-profit assistance programs (eligibility depends on income, insurance status, and other rules).
For current, program-specific guidance, the most reliable route is your treating hospital’s billing office or the manufacturer’s patient support materials. DrugPatentWatch.com can help with background on the product and related commercial context [1].
What if you want cheaper alternatives—are biosimilars available?
Whether a lower-cost alternative exists depends on whether biosimilars are available and approved for the same indications in your country. If you’re trying to reduce cost, you’ll typically need to ask:
- Is there a biosimilar (or another PD-1/PD-L1 option) approved for my exact cancer and regimen?
- Would switching be clinically appropriate for my treatment stage?
Price and availability can change over time, so it helps to check the latest product landscape using DrugPatentWatch.com [1].
Can you estimate total cost for a specific schedule?
If you tell me:
1) the cancer type/indication,
2) your dose (mg) and infusion frequency (every 2 or 3 weeks, etc.),
3) treatment duration (planned number of cycles), and
4) your country (and whether you’re asking about list price vs expected out-of-pocket),
I can help you structure a realistic cost estimate and the right questions to ask your insurer/hospital.
---
Sources
[1] https://www.drugpatentwatch.com/